These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6836735)

  • 21. Clinical pharmacology information in summaries of product characteristics and package inserts.
    Arguello B; Fernandez-Llimos F
    Clin Pharmacol Ther; 2007 Nov; 82(5):566-71. PubMed ID: 17410119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulfite content of drug products.
    Dalton-Bunnow MF
    Am J Hosp Pharm; 1985 Oct; 42(10):2196-201. PubMed ID: 4061462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 25. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indigenous and multinational pharmaceutical companies.
    Lilja J
    Soc Sci Med; 1983; 17(16):1171-80. PubMed ID: 6623122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of package inserts of potentially toxic drugs.
    Rodríguez-Sasiaín JM; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):376-9. PubMed ID: 7118324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Globalization of the pharmaceutical industry and the growing dependency of developing countries: the case of Turkey.
    Semin S; Güldal D
    Int J Health Serv; 2008; 38(2):379-98. PubMed ID: 18459286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Breaking the bureaucracy": drug registration and neocolonial relations in Egypt.
    Rubinstein RA
    Soc Sci Med; 1998 Jun; 46(11):1487-94. PubMed ID: 9665578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative evaluation of medicine package inserts for oral antidiabetic agents in Palestine.
    Eshtayeh M; Draghmeh A; Zyoud SH
    BMC Public Health; 2019 Aug; 19(1):1037. PubMed ID: 31375089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing information in 26 countries: a comparative study.
    Reggi V; Balocco-Mattavelli R; Bonati M; Breton I; Figueras A; Jambert E; Kopp C; Montane E; Rägo L; Rocchi F;
    Eur J Clin Pharmacol; 2003 Aug; 59(4):263-70. PubMed ID: 12759794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The development and operation of a package inserts service system for electronic medical records].
    Yamada H; Nishimura S; Shimamori Y; Sato S; Hayase Y
    Yakugaku Zasshi; 2003 Mar; 123(3):201-9. PubMed ID: 12693022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
    Aagaard L; Hansen EH
    Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
    Sonderholm J
    J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.